Inovio Pharmaceuticals Inc (INO)

[Ubertino]

Zacks Research also provides an analyst broker rating (ABR) which uses a recommendation scale from 1 to 5. This simplified scale may be useful for retail investors who are not fully familiar with different brokerage firms’ rating terminology. On this ratings scale, a 1 would indicate a Strong Buy and a 5 would represent a Strong Sell. Out of the 4 analysts polled, the current ABR for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is standing at 1.4.

Professional Wall Street analysts that track the stock are constantly monitoring the company to assess where they believe shares will be moving in the future. The current consensus target price on the stock is $19.75. This target is compiled by Zacks Research using 4 polled analysts. Because analysts may have widely varying estimates of where the stock is headed, the consensus number becomes useful in trying to evaluate the big picture. Out of these polled analysts, the low end target sits at $13, and the high end of the target range is $31. The last noted analyst revision occurred on 2016-08-19.

http://presstelegraph.com/2016/09/20/key-stock-to-watch-tracking-analyst-ratings-and-earnings-on-shares-of-inovio-pharmaceuticals-inc-nasdaqino/